Catalent Analyst Ratings
Baird Downgrades Catalent to Neutral From Outperform, Price Target Is $63.50
Baird Downgrades Catalent(CTLT.US) to Hold Rating, Maintains Target Price $63.5
Hold Rating on Catalent Amid Deal Uncertainties and Conservative Financial Outlook
RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target
Catalent Analyst Ratings
Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)
Barclays Raises Catalent's Price Target to $63 From $47, Maintains Equalweight Rating
Catalent Analyst Ratings
Barclays Adjusts Catalent Price Target to $63 From $47
Catalent's Resilient Growth and Positive Outlook Reinforce Buy Rating
RBC Capital Sticks to Their Hold Rating for Catalent (CTLT)
Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target Is $48
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)
Catalent Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)
RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target
Catalent Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and Catalent (CTLT)